Cargando…

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Epithelial-mesenchymal transition (EMT) is one mechanism of acquired resistance to inhibitors of the epidermal growth factor receptor-tyrosine kinases (EGFR-TKIs) in non-small cell lung cancer (NSCLC). The precise mechanisms of EMT-related acquired resistance to EGFR-TKIs in NSCLC remain unclear. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Takeshi, Song, Lanxi, Bai, Yun, Kinose, Fumi, Li, Jiannong, Ohaegbulam, Kim C., Muñoz-Antonia, Teresita, Qu, Xiaotao, Eschrich, Steven, Uramoto, Hidetaka, Tanaka, Fumihiro, Nasarre, Patrick, Gemmill, Robert M., Roche, Joëlle, Drabkin, Harry A., Haura, Eric B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720447/ https://www.ncbi.nlm.nih.gov/pubmed/26789630 http://dx.doi.org/10.1371/journal.pone.0147344

Ejemplares similares

Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells
por: Roche, Joëlle, et al.
Publicado: (2013)

Erratum: Roche, J. et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 2013, 5, 334–356
por: Roche, Joëlle, et al.
Publicado: (2016)

The emerging role of class-3 semaphorins and their neuropilin receptors in oncology
por: Nasarre, Patrick, et al.
Publicado: (2014)

Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer
por: Roche, Joëlle, et al.
Publicado: (2017)

Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer
por: Gordian, Edna, et al.
Publicado: (2014)

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
por: Machida, Kazuya, et al.
Publicado: (2010)

Natural air leak test without submergence for spontaneous pneumothorax
por: Uramoto, Hidetaka, et al.
Publicado: (2011)

What is an appropriate material to use with a covering technique to prevent the recurrence of spontaneous pneumothorax?
por: Uramoto, Hidetaka, et al.
Publicado: (2014)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
por: Li, Jiannong, et al.
Publicado: (2010)

What factors predict recurrence of a spontaneous pneumothorax?
por: Uramoto, Hidetaka, et al.
Publicado: (2012)

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
por: Dhawan, Andrew, et al.
Publicado: (2017)

Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report
por: Kuwata, Taiji, et al.
Publicado: (2012)

Sclerosing mediastinitis of unknown origin: Report of a case
por: Oka, Soichi, et al.
Publicado: (2015)

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment
por: Chikaishi, Yasuhiro, et al.
Publicado: (2014)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

A triad of NRP2, DLX and p53 proteins in lung cancer metastasis
por: Drabkin, Harry A., et al.
Publicado: (2017)

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
por: Balko, Justin M, et al.
Publicado: (2006)

Total Vertebrectomy for Non-Small Cell Lung Cancer
por: Kuwata, Taiji, et al.
Publicado: (2012)

Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases
por: YAMAGUCHI, FUMIHIRO, et al.
Publicado: (2014)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2019)

Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2021)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
por: Li, Jiannong, et al.
Publicado: (2013)

Malignant Melanoma of the Nipple: A Case Report
por: Nagata, Yoshika, et al.
Publicado: (2018)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes
por: Hudson, Janella, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer
por: Hanagiri, Takeshi, et al.
Publicado: (2011)

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
por: Gemmill, R M, et al.
Publicado: (2005)

ICG easily detects not only the segmental plane, but also the course and blood distribution of the bronchial artery“case report”
por: Uramoto, Hidetaka, et al.
Publicado: (2018)

Indocyanine green fluorescence detects the blood flow of the bronchial anastomosis for bronchoplasty “case report”
por: Uramoto, Hidetaka, et al.
Publicado: (2020)

Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Nishimatsu, Kanako, et al.
Publicado: (2021)

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2022)

Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC
por: Gohlke, Linus, et al.
Publicado: (2023)

ZEB1 in Pancreatic Cancer
por: Wellner, Ulrich, et al.
Publicado: (2010)

The Curious Case of ZEB1
por: Madany, Mecca, et al.
Publicado: (2018)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: Risk of coexistent double cancer
por: Uramoto, Hidetaka, et al.
Publicado: (2010)

Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
por: Uramoto, Hidetaka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hihr7cnobk6lotcde12nglcu45